文献速递肝病

荟萃分析:代谢功能障碍相关脂肪性肝病中肝硬化的全球患病率与死亡率

Meta-Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-12-19

该荟萃分析系统检索截至2024年6月的多个数据库,纳入35项研究共513,742例MASLD患者,估计肝硬化合并患病率在一般实践场景为3.26%、在高风险场景为14.51%,MASLD肝硬化患者全因死亡率为7.91/100人年。

要点

  • MASLD患者中肝硬化全球合并患病率在一般实践场景为3.26%,在高风险场景为14.51%。
  • 高风险场景下北美和澳大利亚患病率18.38%,高于欧洲10.16%和亚洲9.12%(p=0.007)。
  • MASLD肝硬化患者合并全因死亡率为7.91/100人年(95%CI 4.44-13.71)。

核心结论

  • 该荟萃分析强调MASLD患者中肝硬化患病率较高,并存在显著地理和人口学差异,呼吁改进筛查和管理策略。

研究设计与样本

  • 系统检索PubMed、Ovid MEDLINE、EMBASE、Web of Science和SCOPUS自建库至2024年6月,遵循PRISMA指南,采用随机效应模型进行荟萃分析。
  • 共纳入35项研究,包含513,742例MASLD患者;MASLD人群分为一般实践场景(4项研究)和高风险场景(31项研究,指住院或因适应症转诊肝活检者)。

主要发现

  • MASLD患者中肝硬化全球合并患病率在一般实践场景为3.26%(95%CI 2.47%-4.31%),在高风险场景为14.51%(95%CI 11.22%-18.57%)。
  • 高风险场景下区域患病率:北美和澳大利亚18.38%(95%CI 9.06%-33.75%),欧洲10.16%(95%CI 5.71%-17.44%),亚洲9.12%(95%CI 6.11%-13.40%)(p=0.007)。
  • 基于ICD诊断的肝硬化患病率为27.43%,显著高于肝活检诊断的13.24%(p<0.001)。
  • MASLD肝硬化患者合并全因死亡率为7.91/100人年(95%CI 4.44-13.71)(9项研究)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is responsible for a significant global health burden. Despite this burden, the prevalence and mortality of MASLD-related cirrhosis remain inadequately defined, hindering effective public health strategies. This study aimed to estimate the global prevalence and mortality associated with MASLD-related cirrhosis. METHODS: A systematic search of PubMed, Ovid MEDLINE, EMBASE, Web of Science and SCOPUS was conducted using keywords related to MASLD and cirrhosis from inception of each database used through June 2024. COVIDENCE was used for abstract and manuscript review. MASLD populations were categorised into 'general practice setting' and 'high risk setting', which indicated studies from inpatient setting or those referred for liver biopsy for an indication (elevated liver enzymes). Our data extraction and quality assessment followed PRISMA guidelines. A random-effects model was utilised for meta-analysis. RESULTS: From 7924 identified articles, 35 studies comprising 513,742 patients with MASLD met the inclusion criteria. The pooled global prevalence of cirrhosis among MASLD patients was 3.26% (95% CI: 2.47%-4.31%) in general practice settings (4 studies) and 14.51% (95% CI: 11.22%-18.57%) among those in inpatient settings or referred for liver biopsy (31 studies). Regionally, higher prevalence rates in high-risk settings were observed in North America and Australia (18.38%; 95% CI: 9.06%-33.75%), followed by Europe (10.16%; 95% CI: 5.71%-17.44%) and Asia (9.12%; 95% CI: 6.11%-13.40%) (p = 0.007). Notably, ICD-based diagnoses indicated a significantly higher prevalence of cirrhosis (27.43%) compared to those diagnosed by liver biopsy (13.24%; p < 0.001). The pooled all-cause mortality rate for MASLD-cirrhosis patients was estimated at 7.91 per 100 person-years (95% CI: 4.44-13.71) (9 studies). CONCLUSIONS: This meta-analysis underscores the substantial prevalence of cirrhosis among MASLD patients and highlights significant geographic and demographic variability, calling for improved screening and management strategies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Owrangi S, Paik JM, Golabi P, et al. Meta-Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Aliment Pharmacol Ther. 2024. PMID: 39697043. doi:10.1111/apt.18451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。